Literature DB >> 18839138

Editors' comments on a new trial of activated protein C for persistent septic shock.

Jordi Mancebo, Massimo Antonelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18839138     DOI： 10.1007/s00134-008-1303-5

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  14 in total

1.  Treating sepsis.

Authors:  Richard P Wenzel
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

2.  Risks and benefits of activated protein C treatment for severe sepsis.

Authors:  H Shaw Warren; Anthony F Suffredini; Peter Q Eichacker; Robert S Munford
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

3.  Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.

Authors:  Peter Q Eichacker; Robert L Danner; Anthony F Suffredini; Xizhong Cui; Charles Natanson
Journal:  Crit Care Med       Date:  2005-10       Impact factor: 7.598

4.  Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly.

Authors:  Peter Q Eichacker; Charles Natanson; Robert L Danner
Journal:  N Engl J Med       Date:  2006-10-19       Impact factor: 91.245

5.  The European Society of Intensive Care Medicine (ESICM) and the Surviving Sepsis Campaign (SSC).

Authors:  V Marco Ranieri; Rui P Moreno; Andy Rhodes
Journal:  Intensive Care Med       Date:  2007-02-16       Impact factor: 17.440

6.  Increasing evidence that the risks of rhAPC may outweigh its benefits.

Authors:  Peter Q Eichacker; Charles Natanson
Journal:  Intensive Care Med       Date:  2007-02-15       Impact factor: 17.440

7.  Once is not enough: clinical trials in sepsis.

Authors:  Daniel A Sweeney; Robert L Danner; Peter Q Eichacker; Charles Natanson
Journal:  Intensive Care Med       Date:  2008-10-07       Impact factor: 17.440

8.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

9.  Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.

Authors:  Salmaan Kanji; Marc M Perreault; Clarence Chant; David Williamson; Lisa Burry
Journal:  Intensive Care Med       Date:  2007-02-15       Impact factor: 17.440

10.  Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.

Authors:  Simon Finfer; V Marco Ranieri; B Taylor Thompson; Philip S Barie; Jean-François Dhainaut; Ivor S Douglas; Bengt Gårdlund; John C Marshall; Andrew Rhodes
Journal:  Intensive Care Med       Date:  2008-10-07       Impact factor: 17.440
View more
  3 in total

1.  Prolonging resuscitation and postponing the death of activated protein C or is it?

Authors:  Kaggere Shivalingaiah Paramesh; Jim Zwaal
Journal:  Intensive Care Med       Date:  2009-01-09       Impact factor: 17.440

2.  Surviving sepsis?

Authors:  Kevin B Laupland; David N Fisman
Journal:  Can J Infect Dis Med Microbiol       Date:  2011       Impact factor: 2.471

Review 3.  Year in review in Intensive Care Medicine, 2008: I. Brain injury and neurology, renal failure and endocrinology, metabolism and nutrition, sepsis, infections and pneumonia.

Authors:  Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Johan Groeneveld; Goran Hedenstierna; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Philipp Metnitz; Jerôme Pugin; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2008-12-09       Impact factor: 17.440
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.